TLR9 and non-Hodgkin lymphoma: Several studies have linked mutations in downstream TLR9 signaling (e.g., MYD88) or polymorphism in the TLR9 promoter to the pathogenesis of aggressive NHL10, 32 or increased NHL incidence,33 respectively.